Nautilus Biotechnology, Inc. (NAUT): Price and Financial Metrics
GET POWR RATINGS... FREE!
NAUT Stock Price Chart Interactive Chart >
NAUT Price/Volume Stats
| Current price | $3.54 | 52-week high | $12.38 |
| Prev. close | $3.30 | 52-week low | $3.13 |
| Day low | $3.28 | Volume | 489,100 |
| Day high | $3.59 | Avg. volume | 291,009 |
| 50-day MA | $4.08 | Dividend yield | N/A |
| 200-day MA | $5.03 | Market Cap | 440.60M |
Nautilus Biotechnology, Inc. (NAUT) Company Bio
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating platform technology for quantifying and unlocking the complexity of the proteome. It operates Nautilus Proteomic Analysis Platform, an integrated single-molecule protein analysis platform that leverages a nanofabricated, large-scale, single-molecule protein array, multi-cycle imaging, and machine learning analysis to potentially identify and quantify the proteome. The company was founded in 2016 and is headquartered in Seattle, Washington.
Latest NAUT News From Around the Web
Below are the latest news stories about Nautilus Biotechnology Inc that investors may wish to consider to help them evaluate NAUT as an investment opportunity.
Nautilus Biotechnology, Inc. 2021 Q4 - Results - Earnings Call PresentationThe following slide deck was published by Nautilus Biotechnology, Inc. in conjunction with their 2021 Q4 earnings call.... |
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2021 Financial ResultsSEATTLE, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2021. Fiscal Year 2021 Highlights In June, completed a business combination transaction with ARYA Sciences Acquisition Corp III and became a publicly traded company, with gross proceeds from this transaction totaling approximately $345.5 m |
Nautilus to Participate in the 42nd Annual Cowen Health Care ConferenceSEATTLE, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating virtually in the upcoming 42nd Annual Cowen Health Care Conference. Nautilus’ management is scheduled to present on Monday, March 7th at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the |
Clarius Group, LLC Buys BTC BlackRock Ultra Short-Term Bond ETF, , Vanguard Ultra-Short Bond ...Investment company Clarius Group, LLC (Current Portfolio) buys BTC BlackRock Ultra Short-Term Bond ETF, , Vanguard Ultra-Short Bond ETF, Vanguard FTSE Emerging Markets ETF, iShares Core U.S. |
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the fourth quarter and full year 2021 before market open on Thursday, February 24th, 2022. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, bus |
NAUT Price Returns
| 1-mo | -24.20% |
| 3-mo | -11.50% |
| 6-mo | -27.01% |
| 1-year | -65.83% |
| 3-year | -64.49% |
| 5-year | N/A |
| YTD | -31.66% |
| 2021 | -52.26% |
| 2020 | N/A |
| 2019 | 0.00% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...